A coated microtiter-well, enzyme-linked immunometric assay for quantifyingimmunoreactive trypsinogen in dried blood spots was modified to use time-resolved fluorescence of europium in place of end-point enzymatic color development as the quantificationstep. The streptavidinhorseradish peroxidase and color development solutions supplied as packaged reagents were replaced by europium-labeled avidin, and the signal was developed with commercially available enhancement solution and read by time-resolved fluorescence. The change of label from enzyme to europium increased the dynamic range of the assay by about 5-fold, reduced the detection limit 10-fold, and halved the intra-and interassay imprecision. The improved analytical precision and stabilityof the modified assay resulted in a more precise description of the population distributionof immunoreactivetrypsinogenvalues in newborns, showing less variance in the upper centiles. This effect is of paramount importance when using this assay for neonatal screening for cystic fibrosis. The claimed advantages of lanthanide metals as labels in immunoassays (1, 2) have generated considerable enthusiasm for the use of the time-resolved fluorescence of lanthanide metal chelates as alternatives to measuring isotopes and enzyme activities. Published descriptions of various immunoassays claim improved sensitivity, precision, and dynamic range for immunoassays that use time-resolved fluorescence quantification of europium chelates (3-6). Whether these claims can be supported for assays based on samarium chelates (7) is more questionable. Nonetheless, the recent commercial availability of europium and samarium labeling reagents has considerably simplified the earlier published techniques of labeling with lanthanide metals (8-10).
The claimed advantages of lanthanide metals as labels in immunoassays (1, 2) have generated considerable enthusiasm for the use of the time-resolved fluorescence of lanthanide metal chelates as alternatives to measuring isotopes and enzyme activities. Published descriptions of various immunoassays claim improved sensitivity, precision, and dynamic range for immunoassays that use time-resolved fluorescence quantification of europium chelates (3) (4) (5) (6) . Whether these claims can be supported for assays based on samarium chelates (7) is more questionable. Nonetheless, the recent commercial availability of europium and samarium labeling reagents has considerably simplified the earlier published techniques of labeling with lanthanide metals (8-10).
Logistical considerations constrain most laboratories from usingthe commerciallabeling reagents, however. Although very effective in labeling proteins, these reagents are expensive and have limited stability once reconstituted.
In addition, the quantity of protein that must be labeled in one preparation (0.2 mg of reagent is usually sufficient to label enough IgG for >20 000 assays) is excessive for most laboratories' needs unless several users are preparing labels at the same time.
In an attempt to improve the performance of a commercially available enzyme immunoassay (EIA) of immunoreactive trypsinogen (IRT), we investigated its conversion from enzymatic and colorimetric quantification to the use of Eu(ffl) time-resolved fluorescence. ' The measurement of IRT in dried blood-spot samples taken at 5 days postpartum has been established as the first-line test in screening newborn infants for cystic fibrosis (11) (12) (13) .
ConversionoftheEIA to a time-resolved fluorescence immunoassay (FIA) was effected by replacing the horseradish peroxidase-labeled streptavidin of the EIA with Eu(llI)-labeled avidin. Apart from attempting to produce an IRT assay with advantages of greater precision and stability, we had two additional objectives. First, we investigated the possibility of producing Eu Detection limits of assays. For liquid standards, the FIA gave a detection limit (defined as the mean + 2 SD of the zero standard) of 1.5 ± 0.16 pg of trypsin per well (n = 10). The EIA gave a detection limit of 18.0 ± 3.4 pg/well (n = 10). The equivalent volume of whole blood at 0.43 hematocrit in a punched 3-mm disc from a dried blood spot was determined to be 3.5 ± 0. 16 Linearity and dynamic range of assays. Dose-response curves for liquid trypsin standards are shown in Figure  2 . In the EIA format, the dose-response curve was nowhere unequivocally linear, and curve sensitivity diminished beyond the point of practicability at absorbance values of --1.8, which corresponded to a trypsin protein concentration of -130 g/L. In its FIA format, the curve for liquid standards was linear up to a trypsin concentration of 540 gfL (Figure 2, right) . For dried blood-spot standards, the FIA curve was linear up to 720 gfL whole blood; in EIA format, it extended only to 120 gfL whole blood. Because the critical trypsin decision value for cystic fibrosis screening with this assay is 78 .tgfL whole blood, the narrow dynamic range in the EIA format is a major limitation.
Precision profiles. The precision proffles of the assay in EIA and FIA formats, analyzing both liquid and blood-spot standards, are shown in Figure 3 . These proffles were drawn from 20 duplicate estimations over 10 batchesofanalyses. For the EIA, CVs ranged from 9.5% at 180 p.gfL whole blood to 16.2% at 22.5 g/L whole blood in blood-spot specimens.Corresponding imprecision values for the FIA with the same specimens were 5.8% and 9.2%. For both assays, the variability in the elution of IRT from dried blood spotswas the major contributor to analytical imprecision, compared with using the same assays to analyze liquid samples. Variation in the quantity of blood applied in the dried blood spot also contributed substantially to the scatter of results obtained for any one individual.
Assay interferences.
The background fluorescence countsof the zero standard in the FIA were higher (3350 ± 500) than expected for Eu(ffl)-labeled assays (500 ± 100). This increased background was due primarily to the fluorescence of the plastic used in the manufacture of the microtiter wells (2200 ± 500 counts). Examining different brands of microtiter plates, we found background fluorescence counts of 500-2500 in the Delfia system.In the EIA, the absorbance measured for the zero standard was -0.IA. In both EIA and FIA formats, the background response could be quenched by including unlabeled avidin (10 tg/well). Some portion of the background color and fluorescence was therefore attributable to the nonspecific binding of biotinylated signal antibody to the microtiter wells.
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and reference intervals. We analyzed 1000 neonatal dried blood-spot specimens by EIA and FIA, using the same elution buffer, incubation times,and standards for each assay methodology. The regression equation for the results from these samples was EIA = -15.657 + 0.99 FIA. The population distributions obtained are shown in Figure 4 . The lower end of the distribution of values was seen by the FIA, but was not as clearly defined by the EIA. The EIA also showed a greater variance at higher IRT values than did the FIA. Moreover, the population distribution produced by the EIA procedure had a noticeably longer upper tail than that produced by the FIA, and consequently pro- Using the prepared Eu(IU)-avidin reagent, we successfully converted an ELA for measuring JET to use time-resolved fluorescence. In all aspects the assay performed better in the FIA format than in the EIA format. Changing the label from enzyme to Eu(ffl) reduced the detection limit of the assay from 18.0 to 1.5 pg of trypsin per well for analyzing liquid standards, and from 29.1 to 2.9 pg/well for analyzing dried blood-spot standards. In practice, this allowed the low end of the population distribution of blood-spot JET values to be more clearly defined. Changing the label to EuUII) also increased the dynamic range of the assay so that the upper limits for trypsin increased from 130 to 540 Lg/L for analyzing liquid samples, and from 120 to 720 igfL whole blood for analyzing dried blood spots. In practice, this increase in dynamic range allowed accuracy in assessing high LET values from dried blood-spot specimens, if only because dried blood spots cannot be diluted for reanalysis the way that liquid specimens can.
Changing the label from enzyme to Eu(ffl) improved the intra-assay imprecision for LET measurements from 9.3% to 4.5% at 100 g/L and approximately halved the interassay imprecision across the whole range of the assay for analysis of either liquid orblood-spot samples. 
